The Role of Fractional Vascular Laser Therapy in the Management of Burn Scars
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- University of Manitoba
- Enrollment
- 6
- Locations
- 2
- Primary Endpoint
- reduction in scar appearance
Study Overview
Brief Summary
While the literature tends to support the use of laser therapy in the management of burn scars, there is a definite lack of appropriately powered, randomized controlled trials. Laser therapy can be quite expensive when compared to other treatment modalities for burn scars, and while promising, its true usefulness has yet to be conclusively demonstrated. For this reason, our assessing the effects of fractional vascular lasers on burn scars. It has been hypothesized that the fractional vascular lasers work on mature scars to decrease scar formation, and the fractional laser works on scar that is quiescent to promote remodelling. The retexturing/ resurfacing of the laser theoretically can decrease the visibility of the mesh pattern created by meshed split thickness skin graft).
Objective:
To determine the benefit of fractional vascular laser treatment in improving burn scar height, texture, vascularity and pliability in late burn scars.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- Single (Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 60 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •living in Winnipeg
- •burn scar 6-12 months old
- •Fitzpatrick skin type I-III
- •thermal burn scar on trunk or extremities
Exclusion Criteria
- •open wound
Arms & Interventions
Proximal
location of the scar proximal to heart
Intervention: Fractional Vascular Laser (Device)
Distal
location of scar distal to heart
Intervention: Fractional Vascular Laser (Device)
Outcomes
Primary Outcomes
reduction in scar appearance
Time Frame: every 3 weeks to 15 weeks
examine with modified Vancouver Scar Scale
Secondary Outcomes
No secondary outcomes reported
Investigators
Dr. Sarvesh Logsetty
Principal Investigator
University of Manitoba
